Cargando…

Future therapies for pancreatic carcinoma: Insights into cancer precision medicine

Pancreatic carcinoma (PC) has one of the highest rates of cancer-related death worldwide. Except for surgery, adjuvant chemotherapy, chemoradiotherapy, and immunotherapy have shown various efficacies depending on the stage of the patient. We read the review “Current and emerging therapeutic strategi...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Qiu-Yu, Chen, Zhi-Xue, Zhang, Si, Xue, Ru-Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258281/
https://www.ncbi.nlm.nih.gov/pubmed/35979258
http://dx.doi.org/10.3748/wjg.v28.i22.2523
_version_ 1784741514949165056
author Jiang, Qiu-Yu
Chen, Zhi-Xue
Zhang, Si
Xue, Ru-Yi
author_facet Jiang, Qiu-Yu
Chen, Zhi-Xue
Zhang, Si
Xue, Ru-Yi
author_sort Jiang, Qiu-Yu
collection PubMed
description Pancreatic carcinoma (PC) has one of the highest rates of cancer-related death worldwide. Except for surgery, adjuvant chemotherapy, chemoradiotherapy, and immunotherapy have shown various efficacies depending on the stage of the patient. We read the review “Current and emerging therapeutic strategies in pancreatic cancer: Challenges and opportunities” and offer some opinions that may improve its precision and completeness. This review presents a map of appropriate therapies for PC at different stages. Based on the clinical trial outcomes mentioned in the review, we evaluated the potential therapeutic options for PC and helped explain the contradictory efficacy between different programmed cell death protein 1/programmed cell death ligand 1 clinical trials, which may have resulted from the unique features of PC. Although R0 resection and adjuvant chemotherapy are still the gold standards for PC, new modalities, with or without clinical validation, are needed to establish more specific and precise treatments for PC.
format Online
Article
Text
id pubmed-9258281
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-92582812022-08-16 Future therapies for pancreatic carcinoma: Insights into cancer precision medicine Jiang, Qiu-Yu Chen, Zhi-Xue Zhang, Si Xue, Ru-Yi World J Gastroenterol Letter to the Editor Pancreatic carcinoma (PC) has one of the highest rates of cancer-related death worldwide. Except for surgery, adjuvant chemotherapy, chemoradiotherapy, and immunotherapy have shown various efficacies depending on the stage of the patient. We read the review “Current and emerging therapeutic strategies in pancreatic cancer: Challenges and opportunities” and offer some opinions that may improve its precision and completeness. This review presents a map of appropriate therapies for PC at different stages. Based on the clinical trial outcomes mentioned in the review, we evaluated the potential therapeutic options for PC and helped explain the contradictory efficacy between different programmed cell death protein 1/programmed cell death ligand 1 clinical trials, which may have resulted from the unique features of PC. Although R0 resection and adjuvant chemotherapy are still the gold standards for PC, new modalities, with or without clinical validation, are needed to establish more specific and precise treatments for PC. Baishideng Publishing Group Inc 2022-06-14 2022-06-14 /pmc/articles/PMC9258281/ /pubmed/35979258 http://dx.doi.org/10.3748/wjg.v28.i22.2523 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Letter to the Editor
Jiang, Qiu-Yu
Chen, Zhi-Xue
Zhang, Si
Xue, Ru-Yi
Future therapies for pancreatic carcinoma: Insights into cancer precision medicine
title Future therapies for pancreatic carcinoma: Insights into cancer precision medicine
title_full Future therapies for pancreatic carcinoma: Insights into cancer precision medicine
title_fullStr Future therapies for pancreatic carcinoma: Insights into cancer precision medicine
title_full_unstemmed Future therapies for pancreatic carcinoma: Insights into cancer precision medicine
title_short Future therapies for pancreatic carcinoma: Insights into cancer precision medicine
title_sort future therapies for pancreatic carcinoma: insights into cancer precision medicine
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258281/
https://www.ncbi.nlm.nih.gov/pubmed/35979258
http://dx.doi.org/10.3748/wjg.v28.i22.2523
work_keys_str_mv AT jiangqiuyu futuretherapiesforpancreaticcarcinomainsightsintocancerprecisionmedicine
AT chenzhixue futuretherapiesforpancreaticcarcinomainsightsintocancerprecisionmedicine
AT zhangsi futuretherapiesforpancreaticcarcinomainsightsintocancerprecisionmedicine
AT xueruyi futuretherapiesforpancreaticcarcinomainsightsintocancerprecisionmedicine